Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.96 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8092895 | 0.98 | CCR3 (1.00) | CCR3SIGMAR1KDM4EALDH1A1KMT2A | |
| SCHEMBL11801794 | 0.93 | CCR3 (0.89) | CCR3SIGMAR1KDM4EALDH1A1KMT2A | |
| SCHEMBL8092982 | 0.93 | SIGMAR1 (0.85) | CCR3SIGMAR1KMT2A | |
| SCHEMBL6657649 | 0.93 | CCR3 (0.82) | CCR3SIGMAR1 | |
| SCHEMBL6657455 | 0.91 | CCR3 (0.85) | CCR3SIGMAR1 | |
| SCHEMBL9373668 | 0.87 | CCR3 (0.73) | CCR3SIGMAR1KDM4EALDH1A1KMT2A | |
| SCHEMBL6659913 | 0.87 | CCR3 (0.79) | CCR3SIGMAR1KDM4EALDH1A1KMT2A | |
| SCHEMBL30671729 | 0.86 | SIGMAR1 (0.96) | CCR3SIGMAR1 | |
| SCHEMBL10978434 | 0.86 | CCR3 (0.72) | CCR3SIGMAR1 | |
| SCHEMBL28881215 | 0.85 | SIGMAR1 (0.93) | CCR3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| US-6057371-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, GASTROINTESTINAL DISORDERS, DRUG ABUSE, ANGINA, MIGRAINE, HYPERTENSION AND DEPRESSION | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0591426-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-04-13 | — | — | EP | disclosed |
| WO-1993000313-A2 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1993-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | CCR3 282/4885SIGMAR1 409/4885KDM4E 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.